Licensing status

Publication and contact information


Hodgkin's lymphoma

Discoidin domain receptor tyrosine
kinase 1 (DDR1)

In vitro studies suggest inhibiting DDR1 could help increase the efficacy of chemotherapeutics in Hodgkin's lymphoma. In Hodgkin's lymphoma cells, collagen from the tumor microenvironment induced DDR1 phosphorylation, and small interfering RNA against DDR1 increased cell death of the collagen-treated cells compared with control siRNA. In collagen-treated Hodgkin's lymphoma cells, overexpression of DDR1 protected the cells from etoposide-induced cell death. Next steps could include testing DDR1 inhibition in mouse models using broad-spectrum receptor tyrosine kinase inhibitors such as Sprycel dasatinib and Tasigna nilotinib in combination with chemotherapeutics.
Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market Sprycel to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).
Novartis AG markets Tasigna to treat CML.
Etoposide is a generic topoisomerase inhibitor chemotherapeutic.

SciBX 6(46); doi:10.1038/scibx.2013.1317
Published online Dec. 5, 2013

Patent and licensing status unavailable

Cader, F.Z. et al. Blood; published online Oct. 17, 2013;
Contact: Fathima Zumla Cader, University of Birmingham, Birmingham, U.K.